Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

Summary

The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS. The main questions the trial aims to answer are the following: Is TRX319 safe when administered to patients with progressive forms of MS? At what dose does TRX319 work the best to treat participants with primary and or secondary progressive MS? Is pre-conditioning (with Bendamustine) needed to allow TRX319 to better treat participants with primary and/or secondary progressive MS?

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Primary Progressive Multiple Sclerosis
• Secondary Progressive Multiple Sclerosis (SPMS)
• Multiple Sclerosis
• Multiple Sclerosis (MS) Primary Progressive
• Multiple Sclerosis (MS) Secondary Progressive

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 to 65 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Tr1X, Inc.

Last updated on ClinicalTrials.gov

September 21, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites